Discover 1 curated intelligence briefings related to this specific topic.
The surge in de novo molecular design, powered by $400M infusions and quantum-enhanced AI, has created a critical divergence: software is designing drugs and polymers at a velocity that physical labs and manufacturing plants cannot match.
